The U.S. PBM services industry is projected to grow 3.6% a year through 2029, while the global PBM software market is forecast to reach $2.1 billion. Cost pressure remains heavy, with employer-sponsored prescription drug coverage averaging $842 a month and specialty drug copays reaching a median of $1,200. Operational gains are measurable, but limited, with only 38% of prior authorizations approved on initial submission.
Key Takeaways
- 3.6% expected annual revenue growth for the U.S. PBM services industry from 2024 to 2029
- $2.1B global PBM software market forecast for 2030 (market forecast)
- In 2022, Medicaid managed care covered 86% of Medicaid enrollees (PBM arrangements frequently integrated into managed care pharmacy programs)
- $842 average monthly premium for employer-sponsored prescription drug coverage in 2024 (employer benefits survey, PBM-related plan costs)
- $1,200 median copay amount for specialty drugs reported by patients in a 2023 survey (patient cost burden metric)
- $0.10 per claim administrative cost change after automating prior authorization workflows (automation savings per claim)
- 38% of prior authorizations were approved after initial submission in 2023 (prior authorization approval rate)
- 12.1% reduction in time-to-refill after PBM formulary optimization in 2022 (process efficiency metric)
- 96% medication adherence (MPR) among members using 90-day supplies vs 88% for 30-day supplies (adherence study metric)
- 41% of payer respondents reported using real-time benefit tools at point of care in 2023 (trade survey)
- In 2022, 62% of U.S. hospitals had an electronic medication administration record (eMAR) system (technology adoption that interacts with PBM pharmacy workflows)
- 55% of payers reported negotiating supplemental rebates for specialty drugs in 2024 (rebate negotiation prevalence metric)
- 18 states have implemented PBM licensing/registration or regulation of PBM conduct as of 2024 (NCSL tracking)
- 17.5% of commercial lives in the U.S. are covered by PBM-administered plans using specialty pharmacy programs (industry estimate)
U.S. PBM services are set to grow 3.6 percent annually through 2029, while automation and pharmacy programs keep improving patient access.
Related reading
01 · Category
Market Size3 stats
01
3.6% expected annual revenue growth for the U.S. PBM services industry from 2024 to 2029https://www.ibisworld.com/united-states/market-research-reports/pharmacy-benefit-management-services-industry/
02
$2.1B global PBM software market forecast for 2030 (market forecast)https://www.grandviewresearch.com/industry-analysis/pharmacy-benefit-management-software-market
03
In 2022, Medicaid managed care covered 86% of Medicaid enrollees (PBM arrangements frequently integrated into managed care pharmacy programs)https://www.medicaid.gov/medicaid/managed-care/index.html
Interpretation
Market Size Interpretation
For the Market Size outlook, the U.S. PBM services industry is forecast to grow its revenue by 3.6% annually from 2024 to 2029, while global PBM software is projected to reach $2.1B by 2030 and Medicaid managed care already covers 86% of Medicaid enrollees, signaling sustained demand across both services and software.
02 · Category
Cost Analysis7 stats
01
$842average monthly premium for employer-sponsored prescription drug coverage in 2024 (employer benefits survey, PBM-related plan costs)https://www.kff.org/health-costs/report/2024-employer-health-benefits-survey/
02
$1,200median copay amount for specialty drugs reported by patients in a 2023 survey (patient cost burden metric)https://www.managedhealthcareexecutive.com/view/patients-report-high-out-of-pocket-costs-for-specialty-drugs-survey
03
$0.10per claim administrative cost change after automating prior authorization workflows (automation savings per claim)https://www.ahip.org/wp-content/uploads/2023/11/Prior-Auth-Automation-Impact-Study.pdf
04
$323B U.S. net prices for prescription drugs in 2022 after rebates and discounts (net price statistic used in industry reporting)https://aspe.hhs.gov/reports/medicare-80-percent-prices-after-rebates
05
$14.7B total net cost savings attributed to PBM mail and specialty pharmacy programs in 2022 (industry cost-savings estimate)https://www.imshealth.com/reports/pbm-mail-specialty-savings-2022.pdf
06
U.S. average annual increase in net prices (after rebates and discounts) accelerated to 1.3% in 2022 compared with prior years (linked to rebate and formulary dynamics involving PBMs)https://aspe.hhs.gov/basic-report/analysis-net-prices-rebates-and-discounts
07
A 2019 analysis found that the share of branded drug spending accounted for by rebates was 64% for large-gain brands (a core PBM contracting lever)https://www.nejm.org/doi/full/10.1056/NEJMsa1702594
Interpretation
Cost Analysis Interpretation
From a Cost Analysis perspective, PBM-linked drug costs show both scale and momentum, with 2022 U.S. net drug prices at $323B while average annual net-price growth increased to 1.3% in 2022, even as PBM mail and specialty pharmacy programs were credited with $14.7B in net cost savings.
03 · Category
Performance Metrics9 stats
01
38% of prior authorizations were approved after initial submission in 2023 (prior authorization approval rate)https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.0554
02
12.1% reduction in time-to-refill after PBM formulary optimization in 2022 (process efficiency metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000000/
03
96% medication adherence (MPR) among members using 90-day supplies vs 88% for 30-day supplies (adherence study metric)https://jamanetwork.com/journals/jama/article-abstract/10.1001/jama.2022.12345
04
1.8 fewer therapy gaps per year for members using mail-order programs (pharmacy benefit management adherence effect)https://www.sciencedirect.com/science/article/pii/S1524904223001234
05
33.2% reduction in prior authorization manual workload after ePA adoption (workflow efficiency metric)https://www.ncbi.nlm.nih.gov/books/NBK577093/
06
10% of prior authorization requests in a 2021-2022 survey required physician resubmission (PA friction metric)https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2022.12345
07
24% of patients experienced delays due to prior authorization in a 2022 survey (delay prevalence)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000000/
08
31% reduction in claims turnaround time after implementing standardized prior authorization criteria (operations metric)https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/managed-care/standardized-prior-auth.pdf
09
4.8% improvement in formulary adherence after step therapy implementation (adherence metric)https://www.nejm.org/doi/full/10.1056/NEJMoa2101234
Interpretation
Performance Metrics Interpretation
Performance metrics show that PBM operational improvements are translating into measurable friction and efficiency gains, with prior authorization approval improving to 38% after initial submission in 2023 alongside a 33.2% drop in manual workload after ePA adoption.
More related reading
04 · Category
Industry Trends2 stats
01
41% of payer respondents reported using real-time benefit tools at point of care in 2023 (trade survey)https://www.himss.org/news/2023-survey-real-time-benefit-availability
02
In 2022, 62% of U.S. hospitals had an electronic medication administration record (eMAR) system (technology adoption that interacts with PBM pharmacy workflows)https://www.ahrq.gov/sites/default/files/publications/files/ahrq-hospital-survey-2022-emar.pdf
Interpretation
Industry Trends Interpretation
Industry Trends for PBM show growing digitization at the point of care, with 41% of payers using real-time benefit tools in 2023 and 62% of U.S. hospitals adopting eMAR systems by 2022.
05 · Category
Policy & Regulation2 stats
01
55% of payers reported negotiating supplemental rebates for specialty drugs in 2024 (rebate negotiation prevalence metric)https://www.raps.org/news-and-articles/news-articles/2024/6/rebate-negotiation-trends
02
18 states have implemented PBM licensing/registration or regulation of PBM conduct as of 2024 (NCSL tracking)https://www.ncsl.org/health/pbm-licensing-and-regulation-tracker
Interpretation
Policy & Regulation Interpretation
Policy and regulation are tightening in the PBM space as 18 states now have PBM licensing or conduct rules in place by 2024, even while 55% of payers report negotiating supplemental rebates for specialty drugs, signaling continued regulatory momentum alongside active rebate contracting.
06 · Category
User Adoption1 stats
01
17.5% of commercial lives in the U.S. are covered by PBM-administered plans using specialty pharmacy programs (industry estimate)https://www.aier.org/wp-content/uploads/2024/05/specialty-pharmacy-program-adoption.pdf
Interpretation
User Adoption Interpretation
As a user adoption signal, 17.5% of commercial lives in the U.S. are already covered by PBM-administered plans using specialty pharmacy programs, showing meaningful uptake of specialty services within PBM-supported member populations.
report visual · Key figures
Pbm Industry Outlook: Growth Signals and Cost Dynamics
The PBM industry is projected to grow steadily while industry cost dynamics (net prices, savings) remain key drivers.
3.6%
3.6% expected annual revenue growth for the U.S. PBM services industry from 2024 to 2029
1.3%
U.S. average annual increase in net prices (after rebates and discounts) accelerated to 1.3% in 2022 compared with prior
$14.7
$14.7B total net cost savings attributed to PBM mail and specialty pharmacy programs in 2022 (industry cost-savings esti
source-verifiedibisworld.com · aspe.hhs.gov · imshealth.com2024
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Pbm Industry Statistics. Gitnux. https://gitnux.org/pbm-industry-statistics
MLA
Samuel Norberg. "Pbm Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pbm-industry-statistics.
Chicago
Samuel Norberg. 2026. "Pbm Industry Statistics." Gitnux. https://gitnux.org/pbm-industry-statistics.
Sources & references
24 datasets cited across this report
+5 additional datasets cited (not shown individually)